According to USPSTF guidelines, which hrHPV-based screening interval is recommended for women aged 30-65?

According to USPSTF guidelines, which hrHPV-based screening interval is recommended for women aged 30-65?

• A. Every 3 years with cytology alone
• B. Every 5 years with hrHPV testing alone
• C. Every 5 years with cotesting (hrHPV + cytology)
• D. Every 7 years

Answer: (B)

High-risk HPV testing is used to screen for cervical cancer risk, and for women aged 30 to 65 the recommended interval when using hrHPV testing is every 5 years. This longer interval works because a negative hrHPV result provides strong reassurance that significant precancerous changes are unlikely in the near term, allowing less frequent screening without compromising safety. If cotesting is used—combining hrHPV testing with cytology—the interval remains 5 years as well. Cytology alone is typically done every 3 years, and a 7-year interval isn’t supported. So, the hrHPV-based option is screening every 5 years.

High-risk HPV testing is used to screen for cervical cancer risk, and for women aged 30 to 65 the recommended interval when using hrHPV testing is every 5 years. This longer interval works because a negative hrHPV result provides strong reassurance that significant precancerous changes are unlikely in the near term, allowing less frequent screening without compromising safety. If cotesting is used—combining hrHPV testing with cytology—the interval remains 5 years as well. Cytology alone is typically done every 3 years, and a 7-year interval isn’t supported. So, the hrHPV-based option is screening every 5 years.